TrialThe American journal of gastroenterology2013

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.

Byron Cryer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.